Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SIGA 
SIGA Technologies Inc (SIGA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SIGA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -22.22% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 461.51M USD | Price to earnings Ratio 9.64 | 1Y Target Price 17.53 |
Price to earnings Ratio 9.64 | 1Y Target Price 17.53 | ||
Volume (30-day avg) - | Beta 0.95 | 52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 |
52 Weeks Range 4.48 - 11.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.67 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.33% | Operating Margin (TTM) -32.03% |
Management Effectiveness
Return on Assets (TTM) 14.4% | Return on Equity (TTM) 25.47% |
Valuation
Trailing PE 9.64 | Forward PE 9.81 | Enterprise Value 300868611 | Price to Sales(TTM) 3.84 |
Enterprise Value 300868611 | Price to Sales(TTM) 3.84 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 5.28 | Shares Outstanding 71441104 | Shares Floating 40427794 |
Shares Outstanding 71441104 | Shares Floating 40427794 | ||
Percent Insiders 43.29 | Percent Institutions 51.72 |
Upturn AI SWOT
SIGA Technologies Inc
Company Overview
History and Background
SIGA Technologies Inc. was founded in 1995. It focuses on developing solutions for serious infectious diseases and biodefense threats. Its evolution has centered on government contracts and the development of antiviral drugs, notably TPOXX.
Core Business Areas
- Pharmaceutical Development: Development and commercialization of pharmaceutical products for infectious diseases, particularly those related to biodefense.
- Government Contracts: Securing and fulfilling government contracts for the supply of antiviral drugs and related services.
Leadership and Structure
The leadership team includes a CEO, CFO, and other executives responsible for various departments. The organizational structure is likely hierarchical, given its dependence on government contracts and regulatory compliance.
Top Products and Market Share
Key Offerings
- TPOXX (tecovirimat): TPOXX is an antiviral drug approved for the treatment of smallpox. SIGA holds a significant portion of the market for smallpox countermeasures. It is estimated to have a substantial market share in the US government's biodefense stockpile. Potential competitors include Emergent BioSolutions but TPOXX dominates the current market.
Market Dynamics
Industry Overview
The industry involves biodefense and countermeasures against infectious diseases, driven by government funding and global health security concerns.
Positioning
SIGA is a key player in the biodefense market, particularly for smallpox countermeasures. Its competitive advantage lies in its approved drug, TPOXX, and its established relationship with government agencies.
Total Addressable Market (TAM)
The TAM is difficult to estimate precisely but is tied to government spending on biodefense and emerging infectious disease threats. SIGA's positioning is strong within the section of TAM related to orthopoxvirus countermeasures. Can be in the range of $5 to $10 billion dollars.
Upturn SWOT Analysis
Strengths
- Sole FDA-approved treatment for smallpox (TPOXX)
- Strong relationship with US government agencies
- Significant government contracts
- Proprietary drug development platform
Weaknesses
- High dependence on government contracts
- Limited product diversification
- Potential for generic competition in the future
- Vulnerability to changes in government priorities
Opportunities
- Expansion into other infectious disease treatments
- International market expansion
- Development of next-generation antiviral drugs
- Securing additional government contracts related to biodefense
Threats
- Changes in government funding for biodefense
- Emergence of competing treatments
- Regulatory challenges
- Patent expiration
Competitors and Market Share
Key Competitors
- EBS
- CMRX
Competitive Landscape
SIGA holds a strong position due to TPOXX. Competitors are emerging in the broader biodefense space, but SIGA currently dominates the orthopoxvirus countermeasure market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by government contracts for TPOXX.
Future Projections: Future growth depends on securing new contracts, expanding into new markets, and developing new products.
Recent Initiatives: Recent strategic initiatives likely involve pursuing new government contracts and exploring new indications for TPOXX or other antiviral drugs.
Summary
SIGA Technologies Inc. is a strong company in the biodefense sector, primarily driven by its FDA-approved smallpox treatment, TPOXX, and its established government contracts. Its dependence on government funding and limited product diversification pose some risks. SIGA should focus on expanding its product portfolio and exploring new markets to ensure long-term growth and reduce reliance on a single product and customer.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SIGA Technologies Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 1997-09-09 | CEO & Director Dr. Diem Nguyen M.B.A., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 46 | Website https://www.siga.com |
Full time employees 46 | Website https://www.siga.com | ||
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.